Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2019 Feb 27;8(1):LMT09.
doi: 10.2217/lmt-2018-0013. eCollection 2019 Feb.

Stereotactic body radiation therapy in early-stage NSCLC: historical review, contemporary evidence and future implications

Stephen Abel  1 , Shaakir Hasan  1 , Zachary D Horne  1 , Athanasios Colonias  1 , Rodney E Wegner  1
Affiliations
Review

Stereotactic body radiation therapy in early-stage NSCLC: historical review, contemporary evidence and future implications

Stephen Abel et al. Lung Cancer Manag. .

Abstract

Clinical use of stereotactic body radiation therapy (SBRT) has increased dramatically over the last 2 decades and is the current standard-of-care in cases of inoperable early stage non-small-cell lung cancer. While surgical resection remains the standard-of-care for operable patients, several ongoing clinical trials are investigating the role of SBRT in these operative candidates as well. Taking into consideration the expanding role and utility of SBRT, this paper will: review the historical basis of SBRT; examine landmark trials establishing the framework for the current body of evidence; discuss areas of active and future research; and identify epidemiological trends that are likely to further increase the use of SBRT.

Keywords: non-small-cell lung cancer; stereotactic ablative radiotherapy; stereotactic body radiation therapy; stereotactic radiation.

PubMed Disclaimer

Conflict of interest statement

Financial & competing interests disclosure The authors have no relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript. This includes employment, consultancies, honoraria, stock ownership or options, expert testimony, grants or patents received or pending, or royalties. No writing assistance was utilized in the production of this manuscript.

Figures

<b>Figure 1.</b>
Figure 1.. National Library of Medicine's PubMed publications by year based upon search query.
NSCLC: Non-small-cell lung cancer; SABR: Stereotactic ablative radiotherapy; SBRT: Stereotactic body radiation therapy.
See this image and copyright information in PMC

References

    1. National Cancer Institute Surveillance, Epidemiology, and End Results Program. Cancer stat facts: lung and bronchus cancer. 2018. seer.cancer.gov/statfacts/html/lungb.html
    1. National Comprehensive Cancer Network. NCCN guideline with NCCN evidence blocks - non-small cell lung cancer version 2.2019. 2019. www.nccn.org/professionals/physician_gls/recently_updated.aspx
    1. Ginsberg RJ, Rubinstein LV. Randomized trial of lobectomy versus limited resection for T1 N0 non-small-cell lung cancer. Lung Cancer Study Group. Ann. Thorac. Surg. 1995;60(3):615–622. - PubMed
    1. Fan J, Wang L, Jiang G-N, et al. Sublobectomy versus lobectomy for Stage I non-small-cell lung cancer, a meta-analysis of published studies. Ann. Surg. Oncol. 2012;19(2):661–668. - PubMed
    1. Altorki NK, Yip R, Hanaoka T, et al. Sublobar resection is equivalent to lobectomy for clinical Stage 1A lung cancer in solid nodules. J. Thorac. Cardiovasc. Surg. 2014;147(2):754–764. - PubMed

LinkOut - more resources